Literature DB >> 23502042

Osteoporosis medication adherence: physician perceptions vs. patients' utilization.

Jeffrey R Curtis1, Qian Cai, Sally W Wade, Bradley S Stolshek, John L Adams, Akhila Balasubramanian, Hema N Viswanathan, Joel D Kallich.   

Abstract

Few data are available on physician perceptions of osteoporosis medication adherence. This study compared physician-estimated medication adherence with adherence calculated from their patients' pharmacy claims. Women aged ≥45 years, with an osteoporosis-related pharmacy claim between January 1, 2005 and August 31, 2008, and continuous coverage for ≥12 months before and after first (index) claim, were identified from a commercial health plan population. Prescribing physicians treating ≥5 of these patients were invited to complete a survey on their perception of medication adherence and factors affecting adherence in their patients. Pharmacy claims-based medication possession ratio (MPR) was calculated for the 12-month post-index period for each patient. Physicians who overestimated the percentage of adherent (MPR ≥0.8) patients by ≥10 points were considered "optimistic". Logistic regression assessed physician characteristics associated with optimistic perception of adherence. A total of 376 (17.2%) physicians responded to the survey; 62.0% were male, 58.2% were aged 45 to 60 years, 55.3% had ≥20 years of practice, and 35.4% practiced in an academic setting. Participating physicians prescribed osteoporosis medications for 2748 patients with claims data (mean [SD] age of 62.0 [10.6] years). On average, physicians estimated 67.2% of their patients to be adherent; however, only 40% of patients were actually adherent based on pharmacy data. Optimistic physicians (73.4%) estimated 71.9% of patients to be adherent while only 32.2% of their patients were adherent based on claims data. Physicians in academic settings were more likely to be optimistic than community-based physicians (odds ratio 1.69, 95% CI: 1.01, 2.85). Overestimation of medication adherence may impede physicians' ability to provide high quality care for their osteoporosis patients.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23502042      PMCID: PMC3777338          DOI: 10.1016/j.bone.2013.03.003

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  36 in total

1.  Failure of estrogen plus progestin therapy for prevention.

Authors:  Suzanne W Fletcher; Graham A Colditz
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

Review 2.  Effect of postmenopausal hormone therapy on cardiovascular risk.

Authors:  Jacques E Rossouw
Journal:  J Hypertens Suppl       Date:  2002-05

3.  Osteoporosis treatment options expand.

Authors: 
Journal:  Mayo Clin Health Lett       Date:  2010-11

Review 4.  Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.

Authors:  Marit D Moen; Susan J Keam
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

5.  Tolerability and compliance with risedronate in clinical practice.

Authors:  B Hamilton; K McCoy; H Taggart
Journal:  Osteoporos Int       Date:  2003-04-10       Impact factor: 4.507

6.  The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial.

Authors:  Jackie A Clowes; Nicola F A Peel; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

7.  Patients with osteoporosis prefer once weekly to once daily dosing with alendronate.

Authors:  David Kendler; Annie Wai Chee Kung; Ghada El-Hajj Fuleihan; José Gerardo González González; Keavy A Gaines; Nadia Verbruggen; Mary E Melton
Journal:  Maturitas       Date:  2004-07-15       Impact factor: 4.342

8.  Early discontinuation of treatment for osteoporosis.

Authors:  Anna N A Tosteson; Margaret R Grove; Cristina S Hammond; Megan M Moncur; G Thomas Ray; Gwen M Hebert; Alice R Pressman; Bruce Ettinger
Journal:  Am J Med       Date:  2003-08-15       Impact factor: 4.965

9.  Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study.

Authors:  James A Simon; E Michael Lewiecki; Mary E Smith; Richard A Petruschke; Lixia Wang; Joanne J Palmisano
Journal:  Clin Ther       Date:  2002-11       Impact factor: 3.393

10.  How well do clinicians estimate patients' adherence to combination antiretroviral therapy?

Authors:  Loren G Miller; Honghu Liu; Ron D Hays; Carol E Golin; C Keith Beck; Steven M Asch; Yingying Ma; Andrew H Kaplan; Neil S Wenger
Journal:  J Gen Intern Med       Date:  2002-01       Impact factor: 5.128

View more
  10 in total

1.  Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study.

Authors:  A Shah; D Prieto-Alhambra; S Hawley; A Delmestri; J Lippett; C Cooper; A Judge; M K Javaid
Journal:  Osteoporos Int       Date:  2016-11-03       Impact factor: 4.507

2.  Does a multimethod approach improve identification of medication nonadherence in adolescents with chronic kidney disease?

Authors:  Cozumel S Pruette; Shayna S Coburn; Cyd K Eaton; Tammy M Brady; Shamir Tuchman; Susan Mendley; Barbara A Fivush; Michelle N Eakin; Kristin A Riekert
Journal:  Pediatr Nephrol       Date:  2018-08-16       Impact factor: 3.714

Review 3.  Osteoporosis: a discussion on the past 5 years.

Authors:  Kyle M Schweser; Brett D Crist
Journal:  Curr Rev Musculoskelet Med       Date:  2017-06

4.  Improving adherence to and persistence with oral therapy of osteoporosis.

Authors:  M L Bianchi; P Duca; S Vai; G Guglielmi; R Viti; C Battista; A Scillitani; S Muscarella; G Luisetto; V Camozzi; R Nuti; C Caffarelli; S Gonnelli; C Albanese; V De Tullio; G Isaia; P D'Amelio; F Broggi; M Croci
Journal:  Osteoporos Int       Date:  2015-01-27       Impact factor: 4.507

5.  Validity and Reliability of the Thai Version of the 19-Item Compliance-Questionnaire-Rheumatology.

Authors:  Saranya Panichaporn; Wanwisa Chanapai; Ananya Srisomnuek; Phakhamon Thaweeratthakul; Wanruchada Katchamart
Journal:  Patient Prefer Adherence       Date:  2022-08-17       Impact factor: 2.314

6.  Long-term persistence with anti-osteoporosis drugs after fracture.

Authors:  C Klop; P M J Welsing; P J M Elders; J A Overbeek; P C Souverein; A M Burden; H A W van Onzenoort; H G M Leufkens; J W J Bijlsma; F de Vries
Journal:  Osteoporos Int       Date:  2015-03-31       Impact factor: 4.507

7.  "My patients are better than yours": optimistic bias about patients' medication adherence by European health care professionals.

Authors:  Wendy Clyne; Sarah McLachlan; Comfort Mshelia; Peter Jones; Sabina De Geest; Todd Ruppar; Kaat Siebens; Fabienne Dobbels; Przemyslaw Kardas
Journal:  Patient Prefer Adherence       Date:  2016-09-26       Impact factor: 2.711

8.  Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.

Authors:  T Petranova; M Boyanov; A Shinkov; R Petkova; M Intorcia; E Psachoulia
Journal:  Arch Osteoporos       Date:  2017-12-21       Impact factor: 2.617

9.  Patient-physician discordance in assessment of adherence to inhaled controller medication: a cross-sectional analysis of two cohorts.

Authors:  Cristina Jácome; Ana Margarida Pereira; Rute Almeida; Manuel Ferreira-Magalhaes; Mariana Couto; Luís Araujo; Mariana Pereira; Magna Alves Correia; Cláudia Chaves Loureiro; Maria Joana Catarata; Lília Maia Santos; João Pereira; Bárbara Ramos; Cristina Lopes; Ana Mendes; José Carlos Cidrais Rodrigues; Georgeta Oliveira; Ana Paula Aguiar; Ivete Afonso; Joana Carvalho; Ana Arrobas; José Coutinho Costa; Joana Dias; Ana Todo Bom; João Azevedo; Carmelita Ribeiro; Marta Alves; Paula Leiria Pinto; Nuno Neuparth; Ana Palhinha; João Gaspar Marques; Nicole Pinto; Pedro Martins; Filipa Todo Bom; Maria Alvarenga Santos; Alberto Gomes Costa; Armandina Silva Neto; Marta Santalha; Carlos Lozoya; Natacha Santos; Diana Silva; Maria João Vasconcelos; Luís Taborda-Barata; Célia Carvalhal; Maria Fernanda Teixeira; Rodrigo Rodrigues Alves; Ana Sofia Moreira; Cláudia Sofia Pinto; Pedro Morais Silva; Carlos Alves; Raquel Câmara; Didina Coelho; Diana Bordalo; Ricardo M Fernandes; Rosário Ferreira; Fernando Menezes; Ricardo Gomes; Maria José Calix; Ana Marques; João Cardoso; Madalena Emiliano; Rita Gerardo; Carlos Nunes; Rita Câmara; José Alberto Ferreira; Aurora Carvalho; Paulo Freitas; Ricardo Correia; Joao A Fonseca
Journal:  BMJ Open       Date:  2019-11-07       Impact factor: 2.692

Review 10.  PINP as a biological response marker during teriparatide treatment for osteoporosis.

Authors:  J H Krege; N E Lane; J M Harris; P D Miller
Journal:  Osteoporos Int       Date:  2014-03-06       Impact factor: 4.507

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.